ASTCT Notes
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Source Type: research

Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis in Alternative Donor Stem Cell Transplantation: Immune Reconstitution and Infection Risk
Allogeneic hematopoietic cell transplantation (HSCT) is a curative treatment modality for patients with various hematological malignancies and mainly high risk acute myeloid and lymphatic leukemia. For patients that are in need of transplant and lack human leukocyte antigen (HLA) matched sibling donors the most frequent alternatives are HSCT from HLA matched unrelated (MUD) and haploidentical donors [1,2]. The number of haploidentical stem cell transplantations (haploSCT) is constantly increasing both in the United States and in Europe.Graft versus host disease (GVHD) is a major cause of morbidity and mortality after HSCT ...
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Authors: Arnon Nagler Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 26, 2021 Category: Hematology Source Type: research

Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Anti-Thymocyte Globulin (ATG) Administration Schedules in Allogeneic Stem Cell Transplantation.
Adequate immune reconstitution following allogeneic hematopoietic cell transplantation (HCT) is critical to optimize clinical outcomes, particularly relapse, infection and graft versus host disease (GVHD). Recovery of adaptive immunity is crucial, as it represents the critical mechanism of protection against a variety of viral and fungal pathogens, as well as ensure relapse protection in the long run. Therefore, early T cell reconstitution is crucial to the long-term success of HCT. This is because of the versatility provided by the T cell receptor mediated identification of a wide variety of pathogen and tumor associated ...
Source: Biology of Blood and Marrow Transplantation - October 21, 2021 Category: Hematology Authors: Viktoriya Zelikson, Gary Simmons, Natasha Raman, Elizabeth Krieger, Anatevka Rebiero, Kelly Hawks, May Aziz, Catherine Roberts, Alden Chesney, Jason Reed, Ronald Gress, Amir Toor Source Type: research

Factors Impacting Overall and Event Free Survival Following Post-CAR T-cell Consolidative Hematopoietic Stem Cell Transplant
Hematopoietic stem cell transplant (HSCT) has curative potential in pediatric and adolescent and young adult (AYA) B-ALL patients and is generally indicated in patients 1) in first complete remission (CR) with Ph-negative ALL with minimal residual disease (MRD) positivity at the end of consolidation or who had high-risk genetic features and were MRD-positive at the end of induction),1 2) with primary induction failure and able to achieve a CR, 3) that achieve a second complete remission (CR2) after an early marrow relapse, or 4) are in a third or greater CR. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2021 Category: Hematology Authors: John C. Molina, Seth M. Steinberg, Bonnie Yates, Daniel W. Lee, Lauren Little, Crystal L. Mackall, Haneen Shalabi, Nirali N. Shah Source Type: research

Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia
We describe outcomes after HSCT for congenital amegakaryocytic thrombocytopenia (CAMT; n=86) from 2000 to 2018.Study Design: We conducted an analysis of data collected by the Center for International Blood and Marrow Transplant Research on patients with CAMT receiving therapeutic allogeneic HSCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 17, 2021 Category: Hematology Authors: Maria Cancio, Kyle Hebert, Soyoung Kim, Mahmoud Aljurf, Timothy Olson, Eric Anderson, Lauri Burroughs, Anant Vatsayan, Kasiani Myers, Hasan Hashem, Rabi Hanna, Biljana Horn, Tim Prestidge, Jaap-Jan Boelens, Farid Boulad, Mary Eapen Source Type: research

Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma
High-dose chemotherapy and autologous stem cell transplantation (ASCT) remain the standard of care for transplant-eligible patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) who respond to salvage chemotherapy.1 –3 The therapeutic benefit of ASCT has traditionally been attributed solely to cytoreduction from intensive chemotherapy; however, ASCT has important immunogenic effects which may also underlie some of its anti-tumor efficacy. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 17, 2021 Category: Hematology Authors: Reid W. Merryman, Robert Redd, Erin Jeter, Jeff L. Wong, Kristin McHugh, Carol Reynolds, Matthew Nazzaro, Aine Varden, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCa Source Type: research

Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: a Single-Center Study
Allogeneic hematopoietic stem cell transplantation (alloHCT) is used as a potentially curative therapy for patients with high-risk hematological disorders1. However, patients undergoing alloHCT require profound immunosuppression to preserve graft function and to prevent graft-versus-host disease (GVHD), predisposing them to infectious complications that increase morbidity and risk of mortality2 –4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 14, 2021 Category: Hematology Authors: Abel Santos Carreira, Maria Queralt Salas, Mats Remberger, Igor Novitzky Basso, Arjun Datt Law, Wilson Lam, Ivan Pasic, Dennis Kim, Fotios V. Michelis, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Shahid Husain, Rajat Kumar, Jonas Mattsson Source Type: research

Driving out chronic lymphocytic leukemia with CAR T-cells
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western hemisphere [1]. Better understanding of biologic, genetic and molecular aspects of CLL led to improved appreciation of its heterogeneity and, consequently, the development of more refined risk stratification models [2-12]. These models influenced clinical practice by better informing surveillance strategies, and adapting treatment intensity accordingly. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2021 Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Farah Yassine, Martha E. Gadd, Hong Qin Source Type: research

Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas
Methods that enable monitoring of therapeutic efficacy of autologous chimeric antigen receptor (CAR) T-cell therapy will be clinically useful. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2021 Category: Hematology Authors: Aaron M. Goodman, Kimberly A. Holden, Ah-Reum Jeong, Lisa Kim, Kerry D. Fitzgerald, Eyad Almasri, Graham McLennan, Marcia Eisenberg, Amin H. Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, Dimitrios Tzachanis, Edward D. Ball, Taylor J. Jensen, Razell Source Type: research

Hematopoietic cell transplantation is feasible in patients with prior covid-19 infection
Patients with hematologic malignancies are at high risk for severe Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), due to immunocompromised state from their disease or treatment1. There are limited data on outcomes of patients with prior COVID-19 who proceed to autologous or allogeneic hematopoietic cell transplantation (HCT) and specifically whether such patients are more susceptible to poor outcomes and recurrence of COVID-19 2,3. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 11, 2021 Category: Hematology Authors: Nishi Shah, Parastoo B. Dahi, Doris M. Ponce, Craig S. Sauter, Brian C. Shaffer, David J. Chung, Ioannis Politikos, Richard J. Lin, Sergio A. Giralt, Genovefa Papanicolaou, Lakshmi V. Ramanathan, Miguel-Angel Perales, Mini Kamboj, Gunjan L. Shah, Boglarka Source Type: research

Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia Working Party of European Group for Blood and Marrow Transplantation (SAAWP of EBMT)
Aplastic anemia (AA) is a hematopoietic stem cell disorder characterized by decreased bone marrow cellularity and diminished hematopoiesis. It is a rare life-threatening disorder that can be acquired and idiopathic, or it can arise from a background of an inherited marrow failure syndrome. This difference in etiology has significant implications on treatment decisions and management. For instance, immunosuppression is a therapeutic option for acquired AA but is ineffective for the treatment of the inherited forms of bone marrow failure. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 11, 2021 Category: Hematology Authors: Hind Alotaibi, Mahmoud Aljurf, Regis de Latour, Mansour Alfayez, Andrea Bacigalupo, Riad El Fakih, Hubert Schrezenmeier, Syed Osman Ahmed, Eliane Gluckman, Shahid Iqbal, Britta H öchsmann, Constantijn Halkes, Josu de la Fuente, Nawal Alshehry, Simone Ces Source Type: research

Hematopoietic cell transplantation after CD19 CAR T cell-induced ALL remission confers leukemia-free survival advantage
Long-term remissions after CD19 chimeric antigen receptor (CAR) T cell therapy for refractory/relapsed CD19+ B cell acute lymphoblastic leukemia (B-ALL) are elusive.1-6 A high percentage of subjects achieve initial complete remission (CR), but half of subjects experience a recurrence of disease within 6-18 months from CAR T cell infusion.1, 4, 7 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 10, 2021 Category: Hematology Authors: Corinne Summers, Qian Vicky Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, Prabha Narayanaswamy, Wenjun Huang, Jenna Voutsinas, Adam Brand, Wendy Leisenring, Michael C. Jensen, Julie R. Park, Rebecca A. Gardner Tags: HCT post CAR T cell remission confers LFS benefit Source Type: research

Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis
Chronic graft-versus-host disease (cGVHD) is a major late complication of allogeneic hematopoietic cell transplantation (alloHCT). Chronic GVHD is associated with higher transplant-related morbidity, mortality, infectious complications, prolonged duration of immune suppression, and impaired patient-reported quality of life.1-4 Chronic GVHD represents a major obstacle to recovery and survival following alloHCT. Additionally, a 2015 CIBMTR study demonstrated an increasing incidence of cGVHD including moderate and severe cGVHD, in part related to an increase in number of older adults undergoing HCT, improvement in survival an...
Source: Biology of Blood and Marrow Transplantation - October 9, 2021 Category: Hematology Authors: Vijaya Raj Bhatt, Tao Wang, Karen Chen, Carrie L. Kitko, Margaret L. MacMillan, Joseph A. Pidala, Monzr M. Al Malki, Sherif M. Badawy, Amer Beitinjaneh, Siddhartha Ganguly, Betty Hamilton, Gerhard C. Hildebrandt, Lazaros J. Lekakis, Hongtao Liu, Richard T Source Type: research

Novel cell and immune engagers in optimizing tumor specific immunity post autologous transplant in multiple myeloma
Significant advances in the management of multiple myeloma (MM) during the last few decades have resulted in better patient outcomes, yet MM remains a largely incurable disease. Incorporation of immunomodulatory agents (Imids), proteasome inhibitors and monoclonal antibodies into standard combination therapies is well established and recently novel cellular therapies have been rapidly gaining their place in the management of MM. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 7, 2021 Category: Hematology Authors: Murali Janakiram, Nivedita Arora, Veronika Bachanova, Jeffrey S. Miller Source Type: research

Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life
Though survival outcomes have improved dramatically over the last few decades in newly diagnosed myeloma patients, elderly patients have not yielded the same magnitude of benefit as evidenced by higher rates of reported myeloma-related deaths in patients over the age of 75. This is of particularly importance given this cohort comprises a large proportion of myeloma patients with the median age of diagnosis being 70 years. One contributor to this discrepancy is reduced utilization of high-dose therapy and autologous stem cell transplant (HDT/ASCT) in this population due to concerns for increased toxicity and safety. (Source...
Source: Biology of Blood and Marrow Transplantation - October 6, 2021 Category: Hematology Authors: Nisha S. Josepht, Vikas A. Gupta, Sarah Wyman, Michael Graiser, Jonathan L. Kaufman, Dhwani Almaula, Joel Andrews, Craig Hofmeister, Madhav Dhodapkar, Leonard T. Heffner, Sagar Lonial, Ajay K. Nooka Source Type: research

Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications – a single center experience from India.
A matched sibling donor is available for only 30-40% of patients needing a curative stem cell transplant [SCT] and for Indian patients, the chances of finding a 10/10 HLA identical unrelated donor within small donor registries is about 14% while it potentially could increase to 60% with registries that have more than 1,000,000 registered donors1. Therefore, an increasing number of haplo-identical transplants are being performed in India using the post-transplant cyclophosphamide [PTCY] platform developed by the John Hopkins group2,3. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 1, 2021 Category: Hematology Authors: Biju George, Uday Kulkarni, Sharon Lionel, Anup J Devasia, Fouzia N Aboobacker, Kavitha M Lakshmi, Sushil Selvarajan, Anu Korula, Winsley Rose, George M Varghese, Priscilla Rupali, Balaji V, Joy Sarojini Michael, Asha Abraham, Aby Abraham, Vikram Mathews Source Type: research

Impact of treosulfan exposure on early and long-term clinical outcome in pediatric allogeneic HSCT recipients: a prospective multicenter study
In the past decade, treosulfan has been increasingly used as part of conditioning regimens in pediatric allogeneic hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases1-4. Treosulfan (Trecondi ®) is a prodrug and a water-soluble alkylating agent. It is non-enzymatically, pH-dependently converted into a monoepoxide- and a diepoxide derivative, which are thought to cause DNA alkylation5, 6. Treosulfan has gained popularity, because of its myelo- and immunoablative properties, which are com bined with an apparent favorable toxicity profile. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 30, 2021 Category: Hematology Authors: M Y Eileen C van der Stoep, Alice Bertaina, Dirk Jan A R Moes, Mattia Algeri, Robbert G M Bredius, Frans J W Smiers, Dagmar Berghuis, Emilie P Buddingh, Alexander B Mohseny, Henk-Jan Guchelaar, Franco Locatelli, Juliette Zwaveling, Arjan C Lankester Source Type: research

Effect of donor NKG2D polymorphism on relapse after haploidentical transplantation with post-transplant cyclophosphamide
NKG2D is a transmembrane protein belonging to the C-type lectin-like receptor family, which is encoded by KLRK1 in chromosome 12.[1] It is expressed as a homodimer on natural killer (NK) cells, CD8+ T cells, γδ T cells, most iNKT cells, some CD4+ T cells and innate lymphoid cells.[1-3] It works as an activating receptor in NK cells and a co-stimulatory receptor in CD8+ T cells, iNKT cells and in some cases in γδ T cells.[4-6] NKG2D ligands, including MHC class I chain-related protein A/B (MICA and M ICB) and UL-16 binding protein (ULBP) 1–6, are almost absent in normal cells, although they are...
Source: Biology of Blood and Marrow Transplantation - September 30, 2021 Category: Hematology Authors: Kentaro Ido, Hideo Koh, Asao Hirose, Toshiyuki Seto, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Satoru Nanno, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Masayuki Hino, Hirohisa Nakamae Source Type: research

Risk factors for the incidence of PTLD and the mortality due to PTLD after hematopoietic cell transplantation.
Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of hematopoietic cell transplantation (HCT). PTLD occurs in the setting of posttransplant immune deficiency, which allows B cells transformed by Epstein-Barr virus (EBV) to proliferate.1 Multiple risk factors for PTLD incidence have been described. The most frequently and consistently identified risk factors are previous HCT, T cell depletion ex vivo or in vivo, histocompatibility mismatch between donor and recipient, cord blood donor, and posttransplant EBV DNAemia. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 30, 2021 Category: Hematology Authors: Megan Kinzel, Michelle Dowhan, Amit Kalra, Tyler S. Williamson, Rosy Dabas, Kareem Jamani, Ahsan Chaudhry, Mona Shafey, Victor Jimenez-Zepeda, Peter Duggan, Andrew Daly, Poonam Dharmani-Khan, Faisal Khan, Jan Storek Source Type: research

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature
Acute graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HCT) recipients.1 Despite standard prophylactic measures, the rates of GVHD remain high, with incidence rates ranging from 34% to 65% in the first 100 days post-transplant, and adversely impacts mortality.2,3 Therefore, developing improved GVHD prevention strategies remains a critical goal for successful allogeneic HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 28, 2021 Category: Hematology Authors: Rodney Macedo, Chlo é Pasin, Alex Ganetsky, David Harle, Ximi K. Wang, Kirubel Belay, Lee P. Richman, Austin P. Huffman, Robert H. Vonderheide, Andrew J. Yates, David L. Porter, Ying Wang, Yi Zhang, Ran Reshef Source Type: research

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses
Chimeric antigen receptor T cell (CAR-T) therapy, using autologous T cells redirected toward a tumor-specific antigen, is a useful treatment modality for patients with relapsed/refractory (R/R) hematologic malignancies [1 –3]. The engineered T cells are transduced with a CAR molecule consisting of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR T cell contain signaling domains of costimulatory receptors involved in T cell activation and durability, includin...
Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Juliet Meir, Muhammad Abbas Abid, Muhammad Bilal Abid Source Type: research

Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome
Allogeneic hematopoietic cell transplantation (HCT) has curative potential for several hematologic malignancies. There has been a considerable increase in the number of partially matched (haploidentical) transplantations performed worldwide [1]. Traditionally, haploidentical HCT has been associated with substantial bidirectional alloreactivity, which often results in graft failure or severe graft-versus-host disease (GVHD). However, the use of post-transplantation cyclophosphamide (PTCy) in the haploidentical HCT platform has resulted in improved GVHD rates and overall outcomes comparable to those in fully matched donor HC...
Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Anurag Singh, Christopher E. Dandoy, Min Chen, Soyoung Kim, Carolyn M. Mulroney, Mohamed A. Kharfan-Dabaja, Siddhartha Ganguly, Richard T. Maziarz, Christopher G. Kanakry, Jennifer A. Kanakry, Sagar S. Patel, Joshua A. Hill, Satiro De Oliveir, Randy Tapli Source Type: research

STATE OF THE CAR-T: Risk of Infections with CAR-T Therapy and Determinants of SARS-CoV-2 Vaccine Responses
Chimeric antigen receptor T-cells (CAR-T) are autologous T-cells re-directed towards a tumor-specific antigen and are a successful modality for patients with relapsed/refractory (R/R) hematological malignancies (HM)1-3. The engineered T-cells are transduced with a CAR molecule that consists of an antigen recognition single-chain variable fragment (scFv), a transmembrane domain, and an intracellular signaling domain, CD3 ζ. The intracytoplasmic and transmembrane portions of a second-generation CAR-T contain signaling domains of costimulatory receptors involved in T-cell activation and durability, such as CD3ζ, CD2...
Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Juliet Meir, Muhammad Abbas Abid, Muhammad Bilal Abid Source Type: research

Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients
Allogeneic hematopoietic cell transplantation (HCT) provides a curative potential for several hematologic malignancies. There has been a considerable increase in the number of partially matched (haploidentical) transplants performed globally 1. Traditionally, haploidentical transplants were associated with substantial bidirectional alloreactivity, which often resulted in graft failure or severe graft versus host disease (GVHD). However, the use of post-transplant cyclophosphamide (PTCy) in the haploidentical platform has resulted in improved GVHD rates and comparable overall outcomes to fully matched-donor transplants; thu...
Source: Biology of Blood and Marrow Transplantation - September 26, 2021 Category: Hematology Authors: Anurag Singh, Christopher E. Dandoy, Min Chen, Soyoung Kim, Carolyn M. Mulroney, Mohamed A. Kharfan-Dabaja, Siddhartha Ganguly, Richard T. Maziarz, Christopher G. Kanakry, Jennifer A. Kanakry, Sagar S. Patel, Joshua A. Hill, Satiro De Oliveira, Randy Tapl Source Type: research

Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy
Inter-individual variability in tacrolimus exposure is substantial and caused by multiple patient characteristics, including concomitant medications and CYP3A5 genotype/phenotype. CYP3A5 phenotype is determined by common genetic variation in the CYP3A5 gene. Patients carrying at least one copy of the wild-type, CYP3A5*1 allele are CYP3A5 expressers and have an active CYP3A5 enzyme. Patients carrying two no-function copies of the gene (e.g. CYP3A5*3 or CYP3A5*6 alleles) have no active CYP3A5 enzyme. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2021 Category: Hematology Authors: Amy L. Pasternak, Lauren A. Marcath, Yajing Li, Vy Ngyuen, Christina L. Gersch, James M. Rae, David Frame, Gianni Scappaticci, Kelley M. Kidwell, Daniel L. Hertz Source Type: research

The Beneficial Role of Enhanced γδ T-Cells Reconstitution after Allo-SCT in MRD+ AML
Acute myeloid leukemia (AML) patients with high-risk disease benefit from allogeneic hematopoietic stem cell transplantation (allo-SCT) as consolidation therapy. Despite exhibiting a higher risk of non-relapse mortality (NRM) than conventional chemotherapy, allo-transplanted patients experience lower relapse rates due to the pre-transplantation conditioning regimen with high doses of chemotherapy/radiotherapy and to the infusion of donor T-cells within the graft, that mediate graft-versus-leukemia (GvL) effect [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Lucas C.M. Arruda Tags: The Bottom Line Source Type: research

Donor Ambivalence Exposed
In this edition of Transplant and Cellular Therapy, Gutierrez-Aguirre et al. [1] explore moral distress surrounding peripheral blood stem cell (PBSC) donation from related donors. Moral distress (MD) is attributed to feeling of constraints, knowing the right thing to do yet unable or unwilling to act on it [2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Lauren Chelko Tags: The Bottom Line Source Type: research

ASTCT Notes
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Source Type: research

Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic
The rapid global spread of SARS-CoV-2 (COVID-19) in March 2020 led to major changes to stem cell donor availability and product transportation. Transplantation organizations throughout the world responded by recommending cryopreservation of all unrelated donor hemopoietic progenitor cell (HPC) products before commencing recipient conditioning [1 –4]. Although necessary to enable continued access to unrelated donors, routine cryopreservation may introduce additional risks to both donor and recipient. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Duncan Purtill, Cheryl Hutchins, Glen Kennedy, Andrea McClean, Chris Fraser, Peter J Shaw, Paul Chiappini, Helen Tao, David Ma, Karieshma Kabani, Lijun Bai, Matthew Greenwood, Ashish Bajel, Elizabeth O'Flaherty, David Curtis, Leanne Purins, Travis Perera, Source Type: research

Guidelines for Pediatric Unrelated Cord Blood Transplantation —Unique Considerations
Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic GVHD. In addition, CB has unique properties that make it the stem cell source of choice for some non-malignant conditions such as metabolic disorders. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Ann Dahlberg, Joanne Kurtzberg, Jaap Boelens, Caridad Martinez, Paul Carpenter, American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group Source Type: research

Good Engraftment but Quality and Donor Concerns for Cryopreserved HPC Products Collected During the COVID-19 Pandemic.
The rapid global spread of SARS-CoV-2 (COVID-19) in March 2020 led to major changes to stem cell donor availability and product transportation. Transplant organisations throughout the world responded by recommending cryopreservation of all unrelated donor haemopoietic progenitor cell (HPC) products prior to commencing recipient conditioning (1-4). While necessary to enable continued access to unrelated donors, routine cryopreservation may introduce additional risks to both donor and recipient. Our centres recently reported significant variation in post-thaw CD34 recovery from cryopreserved allogeneic HPC, particularly wher...
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Duncan Purtill, Cheryl Hutchins, Glen Kennedy, Andrea McClean, Chris Fraser, Peter J Shaw, Paul Chiappini, Helen Tao, David Ma, Karieshma Kabani, Lijun Bai, Matthew Greenwood, Ashish Bajel, Elizabeth O'Flaherty, David Curtis, Leanne Purins, Travis Perera, Source Type: research

Real-time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology
Graft-versus-host disease (GvHD) represents a leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT).4-6 GvHD can lead to a high symptomatic burden, decline in functional status and poor quality of life.7,8 Cutaneous GvHD occurs frequently and is the most common presenting sign, highlighting the importance of early dermatologic diagnosis and intervention to mitigate disease progression.9 Acute GvHD (aGvHD) typically presents with a maculopapular rash whereas chronic GvHD (cGvHD) presents with poikiloderma, lichen planus-like, lichen sclerosus-like, morphea-like, and scleroti...
Source: Biology of Blood and Marrow Transplantation - September 24, 2021 Category: Hematology Authors: Rachel E. Reingold, Jilliana Monnier, Marco Ardig ò, Joseph R. Stoll, Maria C. Pena, Japbani K. Nanda, Stephen W. Dusza, Josel D. Ruiz, Lisa Flynn, Antara Afrin, Elizabeth G. Klein, Susan E. Prockop, Melissa P. Pulitzer, Doris M. Ponce, Alina Markova, Ma Source Type: research

American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was employed with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQ), tables, and figures. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2021 Category: Hematology Authors: Michelle K. Yong, Terri Lynn Shigle, Yae-Jean Kim, Paul A. Carpenter, Roy F. Chemaly, Genovefa A. Papanicolaou Source Type: research

American Society of Transplantation and Cellular Therapy Series, #4: Cytomegalovirus Treatment and Management of Resistant or Refractory Infections after Hematopoietic Cell Transplantation
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was taken, with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQs), tables, and figures. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2021 Category: Hematology Authors: Michelle K. Yong, Terri Lynn Shigle, Yae-Jean Kim, Paul A. Carpenter, Roy F. Chemaly, Genovefa A. Papanicolaou Source Type: research

American Society of Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was employed with the goal of better serving clinical providers by publishing each standalone topic in the infectious diseases series as a concise format of frequently asked questions (FAQ), tables, and figures. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2021 Category: Hematology Authors: Michelle K. Yong, Terri Lynn Shigle, Yae-Jean Kim, Paul A. Carpenter, Roy F. Chemaly, Genovefa A. Papanicolaou Source Type: research

Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant – a systematic review and meta-analysis
Allogeneic hematopoietic cell transplant (allo-HCT) has been shown to provide a significant overall survival (OS) benefit in patients with acute myeloid leukemia (AML) and intermediate or poor risk cytogenetics compared to patients that did not undergo allo-HCT in multiple studies.1-4 Similar OS benefits with allo-HCT have been documented in patients with higher-risk myelodysplastic syndromes (MDS).5, 6 The advent of reduced intensity conditioning (RIC) allo-HCT has expanded transplant eligibility for older patients and those with significant comorbidities with favorable outcomes compared to non-transplant strategies. (Sou...
Source: Biology of Blood and Marrow Transplantation - September 19, 2021 Category: Hematology Authors: Jan Philipp Bewersdorf, Cecily Allen, Abu-Sayeef Mirza, Alyssa A. Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Christina Cho, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl Source Type: research

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Outcomes for patients with recurrent multiple myeloma (MM) have improved significantly over the past 2 decades with the advent of new targeted therapies and immune therapy-based strategies, such as monoclonal antibodies. Further improvement is expected with introduction of antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T cells, and bispecific T cell engagers [1 –3]. Thus far, allogeneic hematopoietic cell transplantation (allo-HCT), the original immune-based therapy, has been a potentially curative therapy in this disease, as indicated by long-term survival data [4,5] via an immune-mediated graft-ve...
Source: Biology of Blood and Marrow Transplantation - September 17, 2021 Category: Hematology Authors: Firoozeh Sahebi, Dirk-Jan Eikema, Linda Koster, Nicolaus Kroger, Ellen Meijer, Jaap A. van Doesum, Montserrat Rovira, Yener Koc, Emanuele Angelucci, Didier Blaise, Simona Sammassimo, Andrew McDonald, Concepcion Herrera Arroyo, James F. Sanchez, Edouard Fo Source Type: research

Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBMT
Outcomes for patients with recurrent multiple myeloma (MM) have improved significantly over the past two decades with the advent of new targeted therapies and immune therapy-based strategies such as monoclonal antibodies. Further improvement is expected with introduction of antibody-drug conjugates (ADC), CAR T cells, and bi-specific T cell engagers 1-3. Thus far, allogeneic hematopoietic cell transplantation (allo-HCT), the original immune-based therapy, has been a potentially curative therapy in this disease, as indicated by long-term survival data,4, 5 via an immune-mediated graft-versus-myeloma (GVM) effect 6. (Source:...
Source: Biology of Blood and Marrow Transplantation - September 17, 2021 Category: Hematology Authors: Firoozeh Sahebi, Dirk-Jan Eikema, Linda Koster, Nicolaus Kroger, Ellen Meijer, Jaap A. van Doesum, Montserrat Rovira, Yener Koc, Emanuele Angelucci, Didier Blaise, Simona Sammassimo, Andrew McDonald, Concepcion Herrera Arroyo, James F Sanchez, Edouard For Source Type: research

Return-to-School Practices for Pediatric Hematopoietic Cell Transplantation Recipients during the COVID-19 Pandemic
Although organizations such as Centers for Disease Control and Prevention and American Academy of Pediatrics have published guidelines favoring the resumption of in-person schooling during the coronavirus disease 19 (COVID-19) pandemic, there is no specific guidance on hematopoietic cell transplantation (HCT) recipients ’ safe return to school. We conducted a cross-sectional survey of pediatric HCT physician members of the Pediatric Transplantation and Cellular Therapy Consortium practicing in the United States to describe current return-to-school practices during the COVID-19 pandemic for HCT recipients. (Source: Bi...
Source: Biology of Blood and Marrow Transplantation - September 16, 2021 Category: Hematology Authors: Neel S. Bhatt, Christa Meyer, Lih-Wen Mau, Larisa Broglie, Steven Devine, Sung Won Choi, Jeffery Auletta, Rachel Phelan Source Type: research

Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation
The use of haploidentical or HLA-mismatched unrelated donors (MMUD) allows allogeneic hematopoietic cell transplantation in individuals without suitable matched donors. Post-transplantation cyclophosphamide (PTCy) is used routinely for prevention of graft-versus-host disease in recipients of haploidentical transplants, and its use has been recently explored in MMUD transplantation. Compare the incidence of cytomegalovirus (CMV) reactivation and rate of lymphocyte recovery between PTCy MMUD and alternative transplantation modalities. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2021 Category: Hematology Authors: Jose F Camargo, Yosuke Ebisu, Antonio Jimenez-Jimenez, Yoichiro Natori, Ilona Moroz, Michele I Morris, Maritza Alencar, Anthony D Anderson, Lazaros Lekakis, Amer Beitinjaneh, Mark Goodman, Trent Wang, Denise Pereira, Krishna V. Komanduri Source Type: research

nLower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation
The use of haploidentical or HLA mismatched unrelated donors (MMUD) allows allogeneic hematopoietic cell transplantation (HCT) in individuals without suitable matched donors. Post-transplant cyclophosphamide (PTCy) is used routinely for prevention of graft-versus-host disease (GVHD) in recipients of haploidentical transplants and its use has been recently explored in MMUD transplantation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2021 Category: Hematology Authors: Jose F Camargo, Yosuke Ebisu, Antonio Jimenez-Jimenez, Yoichiro Natori, Ilona Moroz, Michele I Morris, Maritza Alencar, Anthony D Anderson, Lazaros Lekakis, Amer Beitinjaneh, Mark Goodman, Trent Wang, Denise Pereira, Krishna V. Komanduri Source Type: research

Return to School Practices for Pediatric Hematopoietic Cell Transplant Recipients During COVID-19 Pandemic
While organizations such as Centers for Disease Control and Prevention and American Academy of Pediatrics have published guidelines favoring resumption of in-person schooling during COVID-19 pandemic, there is no specific guidance on hematopoietic cell transplant (HCT) recipients ’ safety of returning to school. We conducted a cross-sectional survey of pediatric HCT physician members of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) practicing in the United States (US) to describe current return to school practices during the COVID-19 pandemic for HC T recipients. (Source: Biology of Blood and ...
Source: Biology of Blood and Marrow Transplantation - September 16, 2021 Category: Hematology Authors: Neel S. Bhatt, Christa Meyer, Lih-Wen Mau, Larisa Broglie, Steven Devine, Sung Won Choi, Jeffery Auletta, Rachel Phelan Source Type: research